Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of blue skies and mild temperatures hovering about the Pharmalot campus. To celebrate, yes, we are brewing cups of stimulation again. Our choice today is cinnamon mocha. Feel free to join us or grab a bottle of water, if you prefer. Meanwhile, here is the usual menu of tidbits to start your journey. We hope all goes well today and that you conquer the world. As always, we encourage you to keep in touch and, of course, stay safe — wear a mask. …

A World Health Organization-led effort to supply Covid-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but an internal document shows the agency is shunning the Gilead Sciences (GILD) drug remdesivir, Reuters reports. The draft document says the priorities are to secure monoclonal antibodies in a tight market and to boost purchases and distribution of the cheap steroid dexamethasone, of which it has already booked nearly 3 million courses of treatment for poorer countries.


AstraZeneca (AZN) will start discussing emergency approval of its experimental Covid-19 vaccine with the Food and Drug Administration once it has good trial data from the U.K., South Africa, and Brazil, as it has no indication the regulator would favor U.S. data, Reuters writes. If and when AstraZeneca receives the first statistically reliable efficacy and safety results from those trials, based on more than 25,000 volunteers in total, it would present them to the FDA, even though any readout from an ongoing U.S. trial will be months later.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!